Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial

IMPORTANCE: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating feedback loop via mTORC2. Vistusertib, a dual inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Peter, Zaiss, Matthias, Harper-Wynne, Catherine, Ferreira, Marta, Dubey, Sidharth, Chan, Stephen, Makris, Andreas, Nemsadze, Gia, Brunt, Adrian M., Kuemmel, Sherko, Ruiz, Isabel, Perelló, Antonia, Kendall, Anne, Brown, Janet, Kristeleit, Hartmut, Conibear, John, Saura, Cristina, Grenier, Julien, Máhr, Károly, Schenker, Michael, Sohn, Joohyuk, Lee, Keun Seok, Shepherd, Christopher J., Oelmann, Elisabeth, Sarker, Shah-Jalal, Prendergast, Aaron, Marosics, Patricia, Moosa, Atiyyah, Lawrence, Cheryl, Coetzee, Carike, Mousa, Kelly, Cortés, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865233/
https://www.ncbi.nlm.nih.gov/pubmed/31465093
http://dx.doi.org/10.1001/jamaoncol.2019.2526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865233/
https://www.ncbi.nlm.nih.gov/pubmed/31465093
http://dx.doi.org/10.1001/jamaoncol.2019.2526

Ejemplares similares